Companies /Healthcare

AbCellera Biologics Inc

NASDAQ: ABCL Biotechnology
$12.33
â–² $0.09 (+0.76%) today
Markets open · 2:57pm ET

Q2 2026 Earnings

Reported Aug 5, 2026, 4:18pm ET · SEC source
$-0.18
Miss −9.09%
EPS · est. $-0.17 GAAP
$4.1M
Miss −48.39%
Revenue · est. $7.8M
1 quarter
Consecutive EPS misses

Market Reaction

% change · around the report
0+6%+12%+18%Aug 5Aug 6report 4:18pm ETearnings−0.2%+18.5%
0+6%+12%+18%Aug 5Aug 6earnings−0.2%+18.5%
ABCL +18.5%S&P 500 −0.2%
0+6%+12%+18%Aug 5Aug 6report 4:18pm ETearnings+0.0%+18.5%
0+6%+12%+18%Aug 5Aug 6earnings+0.0%+18.5%
ABCL +18.5%NASDAQ +0.0%
0+30%+60%+90%Aug 4Aug 13report 4:18pm ETearnings+0.9%+95.4%
0+30%+60%+90%Aug 4Aug 13earnings+0.9%+95.4%
ABCL +95.4%S&P 500 +0.9%
0+30%+60%+90%Aug 4Aug 13report 4:18pm ETearnings+2.2%+95.4%
0+30%+60%+90%Aug 4Aug 13earnings+2.2%+95.4%
ABCL +95.4%NASDAQ +2.2%
+10.30%
Day of report
+6.13%
Next session
+67.99%
One week

Did ABCL Beat Earnings? Q2 2026 Results

AbCellera Biologics delivered a sharply disappointing second quarter for fiscal 2026, missing on both the top and bottom lines as a near-collapse in licensing and royalty revenue overshadowed a string of meaningful new partnerships. Total revenue came in at just $4.05 million, falling 76.3% from $17.08 million a year ago and landing well short of the $7.85 million consensus estimate, a 48.39% miss driven largely by licensing and royalty revenue crashing to $149,000 from $10.45 million in Q2 2025. The GAAP net loss widened to $55.43 million, or $0.18 per share, versus a loss of $34.73 million, or $0.12 per share, a year earlier, with the per-share result missing the $0.17 consensus by 9.09% as R&D spending climbed to $45.99 million. Against that backdrop, AbCellera secured over $112 million in combined upfront payments through new TCE platform collaborations with Jazz Pharmaceuticals and Vertex Pharmaceuticals, though the stock still slipped after the Vertex announcement. Investors will look to an expected Phase 2 readout for ABCL635 in August as the next pivotal catalyst.

Key Takeaways
  • Revenue decline driven by lower research fees and significantly reduced licensing and royalty revenue
  • R&D expenses increased due to pipeline investment in internal clinical programs
  • SG&A expenses decreased year-over-year
  • New Jazz and Vertex TCE platform collaborations adding over $112 million in upfront cash

“Last quarter we completed enrollment for the Phase 2 study of ABCL635, and we expect to announce top-line data very soon.”

AbCellera Biologics CEO, on the earnings call

Forward Guidance & Outlook

AbCellera expects ABCL635 Phase 2 top-line data readout in Q3 2026 (August), ABCL575 Phase 1 top-line data readout in Q4 2026, and continued IND-enabling activities for ABCL386 and ABCL688. The company also aims to nominate at least one additional development candidate for IND-enabling activities in 2026. The Jazz collaboration's third program is expected to initiate within 12 months. Total available liquidity exceeds $675 million to fund the company's strategy.

ABCL YoY Financials

Q2 2026 vs Q2 2025 · SEC filings Q2 2025 Q2 2026
$-150,000,000$-100,000,000$-50,000,000$0$17.1M$4.1MRevenue$-85,527,248$-62,777,000Operating Income$-137,229,512$-55,427,000Net Income
$-150,000,000$-100,000,000$-50,000,000$0RevenueOperating IncomeNet Income

ABCL Revenue by Segment

Licensing and Royalty Revenue$149,000
Research Fees$3.9M−41.2%
Licensing Revenue

Figures from SEC filings and company reports. Not investment advice.